Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 114 CHF 0.91% Market Closed
Market Cap: 4.8B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Siegfried Holding AG
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Income from Continuing Operations
CHf128.8m
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Income from Continuing Operations
CHf113.6m
CAGR 3-Years
5%
CAGR 5-Years
18%
CAGR 10-Years
16%
Lonza Group AG
SIX:LONN
Income from Continuing Operations
CHf574m
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
12%
Tecan Group AG
SIX:TECN
Income from Continuing Operations
CHf101.3m
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Income from Continuing Operations
-€51.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Income from Continuing Operations
CHf27.9m
CAGR 3-Years
34%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 192.72 CHF
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Income from Continuing Operations?
Income from Continuing Operations
128.8m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Income from Continuing Operations amounts to 128.8m CHF.

What is Siegfried Holding AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
17%

Over the last year, the Income from Continuing Operations growth was -14%. The average annual Income from Continuing Operations growth rates for Siegfried Holding AG have been 23% over the past three years , 17% over the past five years .

Back to Top